Clinical Trial Detail

NCT ID NCT01853748
Title T-DM1 vs Paclitaxel/Trastuzumab for Breast (ATEMPT Trial)
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements Yes
Sponsors Dana-Farber Cancer Institute
Indications

Her2-receptor positive breast cancer

Therapies

Paclitaxel + Trastuzumab

Ado-trastuzumab emtansine

Age Groups: adult

Additional content available in CKB BOOST